Stocktoria

REPLIGEN CORP RGEN

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1986-04-29 · LEI

REPLIGEN CORP statistics & valuation

Market cap$8.3B
P / E169.6×
P / S11.2×
P / B3.9×
P / FCF88.3×
Net margin6.6%
Return on equity2.3%
FCF margin12.7%
Net cash$23.8M
Net debt / EBITDA-0.2×
Enterprise value USD$8.3B
EV / EBITDA61.7×
Earnings yield EBIT/EV0.7%
Return on capital2%
Graham number -83.8%$26.90

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value ($26.90); a green figure means the price is below it.

Profitability & efficiency

Net margin (%)
11.20% 20.10% 8.60% 7.90% 16.40% 19.10% 23.20% 5.60% -4.00% 6.60% 2016201720182019202020212022202320242025
Gross margin (%)
2016201720182019202020212022202320242025
Operating margin (%)
15.30% 9.90% 13.40% 13.40% 19.10% 24.90% 28.00% 7.50% -5.50% 7.50% 2016201720182019202020212022202320242025
Return on equity (%)
6.90% 4.80% 2.70% 2.00% 3.90% 7.30% 9.70% 1.80% -1.30% 2.30% 2016201720182019202020212022202320242025
Shares outstanding
33.8M 43.6M 45.5M 52.1M 54.8M 55.3M 55.6M 55.8M 56.1M 56.3M 2016201720182019202020212022202320242025
Net debt ($)
-$231.8M -$23.8M 2016201720182019202020212022202320242025
Share buybacks ($)
2016201720182019202020212022202320242025
Return on assets (%)
4.00% 3.80% 2.10% 1.50% 3.10% 5.40% 7.40% 1.30% -0.90% 1.70% 2016201720182019202020212022202320242025
Free cash flow margin (%)
3.10% 8.50% 11.40% 18.00% 11.00% 7.70% 10.90% 12.30% 23.60% 12.70% 2016201720182019202020212022202320242025
Debt / equity (×)
0.27× 0.26× 2016201720182019202020212022202320242025
EPS ($)
$0.34 $0.72 $0.37 $0.44 $1.11 $2.24 $3.24 $0.63 -$0.46 $0.86 2016201720182019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

P / E vs its own history

REPLIGEN CORP trades at about 192.7× earnings — above its 10-year norm (10-year range 49.1×–300.6×, median 154.1×).

49.1× 300.6×

Shaded band = 10-year range (49.1×–300.6×); dot = today's 192.7×.

Historical P/E = month-end price near each fiscal year-end ÷ that year's EPS. A read on whether the stock is cheap or dear relative to how it has typically been valued — not a forecast.

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating margin7.5%-5.5%7.5%28.0%24.9%19.1%13.4%13.4%9.9%15.3%
Net margin6.6%-4.0%5.6%23.2%19.1%16.4%7.9%8.6%20.1%11.2%
FCF margin12.7%23.6%12.3%10.9%7.7%11.0%18.0%11.4%8.5%3.1%
Return on assets1.7%-0.9%1.3%7.4%5.4%3.1%1.5%2.1%3.8%4.0%
Return on equity2.3%-1.3%1.8%9.7%7.3%3.9%2.0%2.7%4.8%6.9%
Debt / equity0.26×0.27×————————
Current ratio8.378.416.742.472.482.8313.282.129.638.74

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.